Featured Research

from universities, journals, and other organizations

Model Predicts Risk Of Breast Cancer For Young Women Treated For Hodgkin Lymphoma

Date:
October 8, 2005
Source:
Journal of the National Cancer Institute
Summary:
Young women who are treated for Hodgkin lymphoma with chest radiation therapy have a high cumulative absolute risk of developing breast cancer later in life. This risk increases with age at end of follow-up, time since diagnosis, and radiation dose, according to a new study in the October 5 issue of the Journal of the National Cancer Institute.

Young women who are treated for Hodgkin lymphoma with chestradiation therapy have a high cumulative absolute risk of developingbreast cancer later in life. This risk increases with age at end offollow-up, time since diagnosis, and radiation dose, according to a newstudy in the October 5 issue of the Journal of the National CancerInstitute.

Due to advances in the treatment of Hodgkin lymphoma,there are now many long-term survivors who are at risk for thedevelopment of secondary cancers that frequently reflect the late sideeffects of treatment. Second primary cancers are the leading cause ofdeath among long-term survivors, and breast cancer is the most commonsecondary cancer in female Hodgkin lymphoma survivors.

Toestimate the future cumulative absolute risk of breast cancer for youngwomen treated for Hodgkin lymphoma, Lois B. Travis, M.D., of theNational Cancer Institute, and colleagues analyzed data from acase-control study within an international population-based cohort of3,817 female 1-year survivors of Hodgkin lymphoma who had beendiagnosed at age 30 or younger between 1965 and 1994.

Thecumulative absolute risk of developing breast cancer increased with ageat end of follow-up, time since diagnosis, and radiation dose. Forexample, a woman who was treated for Hodgkin lymphoma at age 20 with achest radiation dose of at least 40 Gy without alkylating agents wouldhave a 0.4% risk of developing breast cancer by age 30, a 4.9% risk byage 40, and a 19.1% risk by age 50. By comparison, for white women inthe general population, the absolute risks of breast cancer from age 20to ages 30, 40, and 50 are, respectively, 0.04%, 0.5%, and 2.0%.

"However,it should always be noted that the gains in long-term survival providedby successful radiotherapy and chemotherapy outweigh the associatedrisks of breast cancer and other late sequelae. Moreover, currentmodifications in treatment will likely result in lower risks of breastcancer in the future," the authors write.

In an editorial, Dan L.Longo, M.D., of the National Institute on Aging, questions thecontinued routine use of radiation therapy for the treatment of Hodgkindisease when alternative approaches, such as combination chemotherapyalone, have similar success in curing the disease without the magnitudeof late fatal complications. "We need to stop exposing women to therisk of subsequent breast cancer (and other malignancies and heartdisease) by needlessly using radiation therapy as a component of theirHodgkin disease treatment," he writes. "A Pyrrhic victory in theabsence of reasonable alternative ways to accomplish the goal can betragic but necessary; a Pyrrhic victory that could be avoided whilestill accomplishing the goal is just foolish."

###

Citations:
#Article: Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE,Holowaty E, et al. Cumulative Absolute Breast Cancer Risk for YoungWomen Treated for Hodgkin Lymphoma. J Natl Cancer Inst 2005;97:1428
# Editorial: Longo DL. Radiation Therapy in Hodgkin Disease: Why Risk A Pyrrhic Victory? J Natl Cancer Inst 2005;97:1394

Note:The Journal of the National Cancer Institute is published by OxfordUniversity Press and is not affiliated with the National CancerInstitute. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Model Predicts Risk Of Breast Cancer For Young Women Treated For Hodgkin Lymphoma." ScienceDaily. ScienceDaily, 8 October 2005. <www.sciencedaily.com/releases/2005/10/051008203718.htm>.
Journal of the National Cancer Institute. (2005, October 8). Model Predicts Risk Of Breast Cancer For Young Women Treated For Hodgkin Lymphoma. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2005/10/051008203718.htm
Journal of the National Cancer Institute. "Model Predicts Risk Of Breast Cancer For Young Women Treated For Hodgkin Lymphoma." ScienceDaily. www.sciencedaily.com/releases/2005/10/051008203718.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins